SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (187)5/14/2002 5:25:42 PM
From: Czechsinthemail  Read Replies (1) of 598
 
Merck has waived its option to assume responsibility for the development of our anti-cytomegalovirus drug candidate resulting from this Agreement. Merck had paid us $18.4 million in research payments under this agreement through March 1999.

How much significance is there in Merck's declining their option on the anti-cytomegalovirus drug? Is it more likely casting doubt on the likelihood of getting FDA approval or just not a good fit for Merck's sales plans?

Baird
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News